Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

Biogen (NASDAQ:BIIB) had its target price hoisted by equities research analysts at Canaccord Genuity Group from $230.00 to $245.00 in a research report issued to clients and investors on Wednesday,MarketScreener reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 33.64% from the company’s previous close.

Other analysts have also recently issued research reports about the company. Wolfe Research set a $231.00 price target on Biogen in a report on Monday, February 9th. Royal Bank Of Canada upped their price objective on shares of Biogen from $217.00 to $233.00 and gave the stock an “outperform” rating in a research report on Monday, February 9th. Piper Sandler raised their target price on shares of Biogen from $157.00 to $177.00 and gave the company a “neutral” rating in a research note on Monday, February 9th. Citigroup raised their price objective on shares of Biogen from $185.00 to $215.00 and gave the company a “neutral” rating in a research report on Monday, February 9th. Finally, UBS Group began coverage on Biogen in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $185.00 target price on the stock. Twelve research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $207.96.

Biogen Stock Performance

Biogen stock opened at $183.33 on Wednesday. Biogen has a 1-year low of $110.04 and a 1-year high of $202.41. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $26.91 billion, a PE ratio of 20.81, a price-to-earnings-growth ratio of 1.49 and a beta of 0.15. The firm’s 50 day simple moving average is $186.19 and its 200 day simple moving average is $170.98.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter in the prior year, the firm posted $3.44 earnings per share. The business’s quarterly revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, analysts expect that Biogen will post 15.83 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider directly owned 8,043 shares of the company’s stock, valued at $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.18% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Norges Bank bought a new position in Biogen during the 4th quarter worth approximately $464,408,000. Boston Partners bought a new stake in Biogen in the fourth quarter valued at approximately $302,815,000. Fred Alger Management LLC lifted its position in Biogen by 39,074.8% in the fourth quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock valued at $140,576,000 after purchasing an additional 796,735 shares during the last quarter. Employees Provident Fund Board purchased a new stake in shares of Biogen during the fourth quarter valued at approximately $123,931,000. Finally, Orion Porfolio Solutions LLC boosted its stake in shares of Biogen by 6,828.4% during the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock valued at $64,965,000 after purchasing an additional 509,809 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: FDA approval of a higher‑dose SPINRAZA regimen strengthens Biogen’s rare‑disease franchise and supports recurring revenue from an established product. This regulatory win is a near‑term catalyst for revenue stability and offsets some pipeline risk. US FDA approves higher-dose of Biogen’s genetic disorder drug
• Positive Sentiment: Biogen struck a definitive agreement to acquire Apellis for ~$5.6B in cash, adding two commercial drugs (EMPAVELI, SYFOVRE) and nephrology/immunology capabilities that could boost long‑term growth and diversify Biogen beyond MS and Alzheimer’s exposure. The deal includes contingent value rights (CVRs) tied to SYFOVRE sales. Biogen to buy Apellis Pharmaceuticals for $5.6 billion
• Positive Sentiment: Positive Phase II data for litifilimab in cutaneous lupus add to Biogen’s pipeline momentum, indicating incremental R&D upside beyond the transaction and SPINRAZA support. Pipeline wins help the investment narrative over the medium term. Biogen’s second positive Phase II litifilimab trial in CLE
• Neutral Sentiment: Apellis shares jumped sharply (100%+ intraday) after the offer — market evidence the deal values Apellis at a substantial premium; the move itself is a neutral signal for BIIB except insofar as it validates the target’s assets and the premium Biogen paid. Apellis Pharmaceuticals (APLS) Hits 2-Year High on 140% Upside from Biogen Merger
• Neutral Sentiment: Multiple sell‑side analysts maintained Hold ratings on BIIB, noting recent approvals and pipeline progress but flagging execution risks (Leqembi/Alzheimer’s exposure, MS erosion) — consensus remains cautious despite catalysts. Biogen: Spinraza HD Approval Supports but Does Not Transform Outlook
• Negative Sentiment: Biogen shares declined after the deal announcement as investors weighed the cash cost, the premium paid, and near‑term EPS dilution/return on investment uncertainty. The acquisition reduces near‑term financial flexibility and raises execution risk for integrating Apellis. Why Biogen Stock Sank While the Market Soared
• Negative Sentiment: An investor law‑firm investigation into the adequacy of Apellis’s sale process/price emerged, which could slow or complicate closing or create legal distractions — a governance/legal overhang to monitor. Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process
• Negative Sentiment: Some analysts warn the takeover caps upside from an M&A arbitrage view and that near‑term catalysts remain limited, tempering enthusiasm for BIIB until integration progress and SYFOVRE/EMPAVELI commercial traction are visible. Hold Rating on Apellis Reflects Biogen Takeover Cap on Upside and Limited Near-Term Catalysts

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.